Lead drug from J&J and Addex’s 20-year collaboration flunks Phase 2 in epilepsy

The top ex­per­i­men­tal drug stem­ming from John­son & John­son’s long-run­ning al­liance with Ad­dex Ther­a­peu­tics has failed a Phase 2 epilep­sy study, cast­ing a shad­ow over its fu­ture.

The can­di­date, ADX71149, did not make a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in time to base­line seizure count when added to the stan­dard of care. Ad­dex is still an­a­lyz­ing the da­ta and will work with its part­ner, J&J, to de­ter­mine the next steps for the pro­gram, Chief Med­ical Of­fi­cer Roger Mills said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.